Sacubitril-Valsartan Initiation in Chronic Heart Failure Patients Impacts Sleep Apnea: The ENTRESTO-SAS Study
ESC Heart Failure

Abstract
Optimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation based on six studies encompassing a total of 67 patients only. Whether sacubitril–valsartan (SV), a cornerstone of HFrEF medical treatment, impacts SA is unknown and requires evaluation.
The ENTRESTO-SAS trial is a six-centre, prospective, open-label real-life cohort study (
In this real-life population, SV treatment for 3 months in SA patients is associated with a significant decrease in AHI. These results support the current guidelines that recommend first an optimization of the HFrEF treatment in patients with HFrEF and central SA. A potential positive airway pressure sparing effect merits further investigation.
Contributors

Dany Jaffuel
Author

Erika Nogue
Author

Philippe Berdague
Author

Michel Galinier
Author

Pauline Fournier
Author

Marion Dupuis
Author

Frédéric Georger
Author

Marie-Pierre Cadars
Author

Jean-Etienne Ricci
Author

Nathalie Plouvier
Author

François Picard
Author

Vincent Puel
Author

Jean-Pierre Mallet
Author

Carey M. Suehs
Author

Nicolas Molinari
Author

Arnaud Bourdin
Author



